CVS Caremark is facing a class-action lawsuit over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 weight-loss drug.

The suit was filed on behalf of two people who lost Zepbound coverage through their employer-sponsored health care plan, though the lawsuit says some 200,000 people were impacted by Caremark’s decision. Zepbound patients whose employers use CVS Caremark as a pharmacy benefits manager were told they’d have to switch to Wegovy, a similar drug that studies have shown is less effective than Zepbound for treating obesity .

Why is CVS Caremark being sued?

The lawsuit accuses Caremark, the nation’s largest pharmacy benefit manager, of denying medically necessary drugs in violation of federal law. CVS Caremark stopped covering Zepbound on July 1 after

See Full Page